Atara Biotherapeutics/ATRA

$0.84

9.05%
-
1D1W1MYTD1YMAX

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through the incorporation of engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). Its pipeline products include Tab-cel, ATA188, ATA2271, ATA3271, and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is used for the treatment of multiple sclerosis.
Ticker
ATRA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Pascal Touchon
Employees
308
Headquarters
Thousand oaks, United States

ATRA Metrics

BasicAdvanced
$78.54M
Market cap
-
P/E ratio
-$2.77
EPS
0.68
Beta
-
Dividend rate

What the Analysts think about ATRA

Analyst Ratings

Majority rating from 7 analysts.
Hold

Price Targets

Average projection from 4 analysts.
475% upside
High $13.00
Low $0.50
$0.84
Current price
$4.83
Average price target

ATRA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3,319.04% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$2.1M
133.33%
Net income
$-69.7M
-1.97%
Profit margin
-3,319.04%
-57.99%

ATRA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.3%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.72
-$0.72
-$0.68
-$0.66
-
Expected
-$0.51
-$0.39
-$0.67
-$0.66
-$0.48
Surprise
41.83%
83.81%
1.13%
-0.3%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Atara Biotherapeutics stock

Buy or sell Atara Biotherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing